{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:01:54Z","timestamp":1784869314140,"version":"3.55.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03960-8","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:32:20Z","timestamp":1750768340000},"page":"4342-4358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4858-9400","authenticated-orcid":false,"given":"Jos\u00e9 Dario","family":"Portillo-Mi\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhon Jairo","family":"Calder\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ruiz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"3960_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study. EClinicalMedicine. 2022;47: 101404.","journal-title":"EClinicalMedicine"},{"key":"3960_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, et al. Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40:949\u201382.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"3960_CR3","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1002\/onco.13887","volume":"26","author":"E Chang","year":"2021","unstructured":"Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, et al. Systematic review of PD-1\/PD-l1 inhibitors in oncology: from personalized medicine to public health. Oncologist. 2021;26(10):e1786\u201399.","journal-title":"Oncologist"},{"issue":"2","key":"3960_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2 2022, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"3960_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"key":"3960_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-011-9280-5","author":"TJ Stewart","year":"2011","unstructured":"Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 2011. https:\/\/doi.org\/10.1007\/s10555-011-9280-5.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3960_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022;12(3):670\u201391.","journal-title":"Cancer Discov"},{"key":"3960_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923477","volume":"13","author":"R Deng","year":"2022","unstructured":"Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of Helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol. 2022;13: 923477.","journal-title":"Front Immunol"},{"key":"3960_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00767-w","author":"Y Hirata","year":"2023","unstructured":"Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. 2023. https:\/\/doi.org\/10.1038\/s41571-023-00767-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3960_CR10","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264\u201379.","journal-title":"CA Cancer J Clin"},{"issue":"10251","key":"3960_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet"},{"issue":"5","key":"3960_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"key":"3960_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01282-8","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022. https:\/\/doi.org\/10.1186\/s13045-022-01282-8.","journal-title":"J Hematol Oncol"},{"key":"3960_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.008","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024. https:\/\/doi.org\/10.1016\/j.trecan.2024.03.008.","journal-title":"Trends Cancer"},{"issue":"3","key":"3960_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"3960_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0297","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0297.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"3960_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"3960_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.54","author":"C Engblom","year":"2016","unstructured":"Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016. https:\/\/doi.org\/10.1038\/nrc.2016.54.","journal-title":"Nat Rev Cancer"},{"key":"3960_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00546-2","author":"ST Barry","year":"2023","unstructured":"Barry ST, Gabrilovich DI, Sansom OJ, et al. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023. https:\/\/doi.org\/10.1038\/s41568-022-00546-2.","journal-title":"Nat Rev Cancer"},{"key":"3960_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021. https:\/\/doi.org\/10.1038\/s41577-020-00490-y.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3960_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","volume":"39","author":"TX Cui","year":"2013","unstructured":"Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611\u201321.","journal-title":"Immunity"},{"key":"3960_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","volume":"66","author":"T Condamine","year":"2015","unstructured":"Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015;66:97\u2013110.","journal-title":"Annu Rev Med"},{"key":"3960_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/nature13638","author":"D Di Mitri","year":"2014","unstructured":"Di Mitri D, Toso A, Chen JJ, Sarti M, Pinton S, Jost TR, D\u2019Antuono R, Montani E, Garcia-Escudero R, Guccini I, Da Silva-Alvarez S, Collado M, Eisenberger M, Zhang Z, Catapano C, Grassi F, Alimonti A. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2014. https:\/\/doi.org\/10.1038\/nature13638.","journal-title":"Nature"},{"issue":"1","key":"3960_CR24","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","volume":"8","author":"H Liang","year":"2017","unstructured":"Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017;8(1):1736.","journal-title":"Nat Commun"},{"key":"3960_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/nature20554","author":"O De Henau","year":"2016","unstructured":"De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, Wolchok JD, Merghoub T. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature. 2016. https:\/\/doi.org\/10.1038\/nature20554.","journal-title":"Nature"},{"issue":"3","key":"3960_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"7","key":"3960_CR27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/jgh.13284","volume":"31","author":"A Hirbod-Mobarakeh","year":"2016","unstructured":"Hirbod-Mobarakeh A, Mirghorbani M, Hajiju F, Marvi M, Bashiri K, Rezaei N. Myeloid-derived suppressor cells in gastrointestinal cancers: A systematic review. J Gastroenterol Hepatol julio de. 2016;31(7):1246\u201356.","journal-title":"J Gastroenterol Hepatol julio de"},{"issue":"10","key":"3960_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1494113","volume":"7","author":"PF Wang","year":"2018","unstructured":"Wang PF, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, et al. Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies. Oncoimmunology. 2018;7(10): e1494113.","journal-title":"Oncoimmunology"},{"key":"3960_CR29","doi-asserted-by":"crossref","unstructured":"Shibata M, Gonda K, Nakajima T, Matsumoto Y, Nakamura I, Ohki S, Ohtake T, Kumamoto K,, Shimura T, Takenoshita S, Abe N, Momma T. Pretreatment serum levels of circulating myeloidderived suppressor cells (MDSC) as a prognostic indicator in patients with gastrointestinal cancer. In ASCO Annual Meeting 2014; Chicago","DOI":"10.1200\/jco.2014.32.15_suppl.3059"},{"issue":"10","key":"3960_CR30","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380\u201396.","journal-title":"J Clin Invest"},{"issue":"17","key":"3960_CR31","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res. 2017;23(17):5187\u2013201.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3960_CR32","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-20-3564","volume":"81","author":"R Li","year":"2021","unstructured":"Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, et al. Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer. Cancer Res. 2021;81(12):3295\u2013308.","journal-title":"Cancer Res"},{"issue":"1","key":"3960_CR33","doi-asserted-by":"publisher","first-page":"2131084","DOI":"10.1080\/2162402X.2022.2131084","volume":"11","author":"Y Tang","year":"2022","unstructured":"Tang Y, Zhou C, Li Q, Cheng X, Huang T, Li F, et al. Targeting depletion of myeloid-derived suppressor cells potentiates PD-L1 blockade efficacy in gastric and colon cancers. Oncoimmunology. 2022;11(1):2131084.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3960_CR34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.18632\/oncotarget.6662","volume":"7","author":"L Pinton","year":"2015","unstructured":"Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget. 2015;7(2):1168\u201384.","journal-title":"Oncotarget"},{"issue":"10","key":"3960_CR35","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1002\/eji.200939892","volume":"39","author":"V Bronte","year":"2009","unstructured":"Bronte V. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol. 2009;39(10):2670\u20132.","journal-title":"Eur J Immunol"},{"key":"3960_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016. https:\/\/doi.org\/10.1038\/ncomms12150.","journal-title":"Nat Commun"},{"key":"3960_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-023-00681-0","author":"JJ Calderon","year":"2023","unstructured":"Calderon JJ, Prieto K, Lasso P, et al. Modulation of myeloid-derived suppressor cells in the tumor microenvironment by natural products. Arch Immunol Ther Exp. 2023. https:\/\/doi.org\/10.1007\/s00005-023-00681-0.","journal-title":"Arch Immunol Ther Exp"},{"issue":"4","key":"3960_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41568-022-00544-4","volume":"23","author":"A van Weverwijk","year":"2023","unstructured":"van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer abril de. 2023;23(4):193\u2013215.","journal-title":"Nat Rev Cancer abril de"},{"issue":"4","key":"3960_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812\u201330.","journal-title":"Immunity"},{"issue":"10","key":"3960_CR40","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1172\/JCI45862","volume":"121","author":"T Lu","year":"2011","unstructured":"Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest octubre de. 2011;121(10):4015\u201329.","journal-title":"J Clin Invest octubre de"},{"issue":"7","key":"3960_CR41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med julio de. 2007;13(7):828\u201335.","journal-title":"Nat Med julio de"},{"issue":"4","key":"3960_CR42","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1172\/JCI60083","volume":"123","author":"D Vasquez-Dunddel","year":"2013","unstructured":"Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580\u20139.","journal-title":"J Clin Invest"},{"issue":"1","key":"3960_CR43","volume":"2","author":"C R\u00e9b\u00e9","year":"2013","unstructured":"R\u00e9b\u00e9 C, V\u00e9gran F, Berger H, Ghiringhelli F. STAT3 activation: A key factor in tumor immunoescape. JAKSTAT. 2013;2(1): e23010.","journal-title":"JAKSTAT"},{"issue":"5164","key":"3960_CR44","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell","year":"1994","unstructured":"Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415\u201321.","journal-title":"Science"},{"issue":"10","key":"3960_CR45","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1084\/jem.20080132","volume":"205","author":"P Cheng","year":"2008","unstructured":"Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205(10):2235\u201349.","journal-title":"J Exp Med"},{"issue":"16","key":"3960_CR46","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839\u201349.","journal-title":"Cancer Res"},{"issue":"12","key":"3960_CR47","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1002\/ijc.28622","volume":"134","author":"PL Raber","year":"2014","unstructured":"Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014;134(12):2853\u201364.","journal-title":"Int J Cancer"},{"issue":"7","key":"3960_CR48","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","volume":"190","author":"J Yu","year":"2013","unstructured":"Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783\u201397.","journal-title":"J Immunol"},{"key":"3960_CR49","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","volume":"5","author":"V Bronte","year":"2005","unstructured":"Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641\u201354.","journal-title":"Nat Rev Immunol"},{"issue":"6\u20137","key":"3960_CR50","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","volume":"41","author":"P Raber","year":"2012","unstructured":"Raber P, Ochoa AC, Rodr\u00edguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest. 2012;41(6\u20137):614\u201334.","journal-title":"Immunol Invest"},{"issue":"6","key":"3960_CR51","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1164\/rccm.201708-1707OC","volume":"198","author":"Y Yamauchi","year":"2018","unstructured":"Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V. Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer. Am J Respir Crit Care Med. 2018;198(6):777\u201387.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3960_CR52","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1002\/jcp.26896","volume":"234","author":"E Safarzadeh","year":"2019","unstructured":"Safarzadeh E, Hashemzadeh S, Duijf PHG, Mansoori B, Khaze V, Mohammadi A, et al. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer. J Cell Physiol. 2019;234(4):3515\u201325.","journal-title":"J Cell Physiol"},{"issue":"2","key":"3960_CR53","doi-asserted-by":"publisher","first-page":"794","DOI":"10.4049\/jimmunol.1202088","volume":"190","author":"L Wang","year":"2013","unstructured":"Wang L, Chang EWY, Wong SC, Ong SM, Chong DQY, Ling KL. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins. J Immunol. 2013;190(2):794\u2013804.","journal-title":"J Immunol"},{"issue":"19","key":"3960_CR54","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"AL Chang","year":"2016","unstructured":"Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 2016;76(19):5671\u201382.","journal-title":"Cancer Res"},{"issue":"9","key":"3960_CR55","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-15-1823","volume":"23","author":"YG Najjar","year":"2017","unstructured":"Najjar YG, Rayman P, Jia X, Pavicic PG, Rini BI, Tannenbaum C, et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1\u03b2, IL8, CXCL5, and Mip-1\u03b1. Clin Cancer Res. 2017;23(9):2346\u201355.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3960_CR56","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","volume":"24","author":"H Katoh","year":"2013","unstructured":"Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013;24(5):631\u201344.","journal-title":"Cancer Cell"},{"key":"3960_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.990463","author":"H Sui","year":"2022","unstructured":"Sui H, Dongye S, Liu X, Xu X, Wang L, Jin CQ, et al. Immunotherapy of targeting MDSCs in tumor microenvironment. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.990463.","journal-title":"Front Immunol"},{"key":"3960_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.004","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. Mdsc: Markers, development states and unaddressed complexity. Immunity. 2021. https:\/\/doi.org\/10.1016\/j.immuni.2021.04.004.","journal-title":"Immunity"},{"issue":"6","key":"3960_CR59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ccell.2021.05.016","volume":"39","author":"MO Li","year":"2021","unstructured":"Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, et al. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021;39(6):725\u20139.","journal-title":"Cancer Cell"},{"key":"3960_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","author":"H Alshetaiwi","year":"2020","unstructured":"Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.aay6017.","journal-title":"Sci Immunol"},{"issue":"23","key":"3960_CR61","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964\u201374.","journal-title":"Cancer Res"},{"key":"3960_CR62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205085120","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, et al. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023. https:\/\/doi.org\/10.1073\/pnas.2205085120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"3960_CR63","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-05-3755","volume":"66","author":"R Yang","year":"2006","unstructured":"Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, Roden RBS. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 2006;66(13):6807\u201315.","journal-title":"Cancer Res"},{"issue":"5","key":"3960_CR64","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"5","key":"3960_CR65","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7\u2013H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med mayo de. 2003;9(5):562\u20137.","journal-title":"Nat Med mayo de"},{"key":"3960_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019. https:\/\/doi.org\/10.1186\/s12943-018-0928-4.","journal-title":"Mol Cancer"},{"issue":"5","key":"3960_CR67","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1152\/ajpgi.00372.2010","volume":"299","author":"A Bhattacharyya","year":"2010","unstructured":"Bhattacharyya A, Chattopadhyay R, Hall EH, Mebrahtu ST, Ernst PB, Crowe SE. Mechanism of hypoxia-inducible factor 1 alpha-mediated Mcl1 regulation in Helicobacter pylori-infected human gastric epithelium. Am J Physiol Gastrointest Liver Physiol. 2010;299(5):1177\u201386.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3960_CR68","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00372.2010","author":"C Ucaryilmaz Metin","year":"2022","unstructured":"Ucaryilmaz Metin C, Ozcan G. The HIF-1\u03b1 as a potent inducer of the hallmarks in gastric cancer. Cancers (Basel). 2022. https:\/\/doi.org\/10.1152\/ajpgi.00372.2010.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3960_CR69","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/0008-5472.CAN-13-2584","volume":"74","author":"G Liu","year":"2014","unstructured":"Liu G, Bi Y, Shen B, Yang H, Zhang Y, Wang X, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1\u03b1-dependent glycolysis. Cancer Res. 2014;74(3):727\u201337.","journal-title":"Cancer Res"},{"issue":"2","key":"3960_CR70","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","volume":"44","author":"V Kumar","year":"2016","unstructured":"Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. CD45 phosphatase inhibits stat3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity. 2016;44(2):303\u201315.","journal-title":"Immunity"},{"issue":"7754","key":"3960_CR71","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature mayo de. 2019;569(7754):73\u20138.","journal-title":"Nature mayo de"},{"issue":"4","key":"3960_CR72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/vaccines4040036","volume":"4","author":"V Umansky","year":"2016","unstructured":"Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel). 2016;4(4):36.","journal-title":"Vaccines (Basel)"},{"key":"3960_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12469","volume":"1319","author":"S Solito","year":"2014","unstructured":"Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319:47\u201365.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"3960_CR74","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/gutjnl-2018-316324","volume":"68","author":"C Lin","year":"2019","unstructured":"Lin C, He H, Liu H, Li R, Chen Y, Qi Y, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019;68(10):1764\u201373.","journal-title":"Gut"},{"key":"3960_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.862462","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Zhang W, Bai J, Li J, Li H. Emerging role of helicobacter pylori in the immune evasion mechanism of gastric cancer: an insight into tumor microenvironment pathogen interaction. Front Oncol. 2022;12: 862462.","journal-title":"Front Oncol"},{"key":"3960_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015. https:\/\/doi.org\/10.1038\/cddis.2015.162.","journal-title":"Cell Death Dis"},{"issue":"5","key":"3960_CR77","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/jso.23281","volume":"107","author":"H Saito","year":"2013","unstructured":"Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol. 2013;107(5):517\u201322.","journal-title":"J Surg Oncol"},{"issue":"6","key":"3960_CR78","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ. T cell exhaustion. Nat Immunol junio de. 2011;12(6):492\u20139.","journal-title":"Nat Immunol junio de"},{"issue":"7","key":"3960_CR79","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1002\/cam4.2892","volume":"9","author":"R Zhao","year":"2020","unstructured":"Zhao R, Liu Z, Xu W, Song L, Ren H, Ou Y, et al. Helicobacter pylori infection leads to KLF4 inactivation in gastric cancer through a TET1-mediated DNA methylation mechanism. Cancer Med. 2020;9(7):2551\u201363.","journal-title":"Cancer Med"},{"key":"3960_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23309","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wu X, Tian Y, Zhang W, Qiao S, Xu W, et al. H. pylori infection induces CXCL8 expression and promotes gastric cancer progress through downregulating KLF4. Mol Carcinog. 2021. https:\/\/doi.org\/10.1002\/mc.23309.","journal-title":"Mol Carcinog"},{"issue":"2","key":"3960_CR81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jcmgh.2017.01.004","volume":"3","author":"JL Merchant","year":"2017","unstructured":"Merchant JL, Ding L. Hedgehog signaling links chronic inflammation to gastric cancer precursor lesions. Cell Mol Gastroenterol Hepatol. 2017;3(2):201\u201310.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3960_CR82","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.biopha.2019.01.018","volume":"111","author":"Y Yao","year":"2019","unstructured":"Yao Y, Zhou D, Shi D, Zhang H, Zhan S, Shao X, et al. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. Biomed Pharmacother. 2019;111:993\u20131004.","journal-title":"Biomed Pharmacother"},{"key":"3960_CR83","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2021.06.007","volume":"518","author":"V Koh","year":"2021","unstructured":"Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins JA, Ito Y, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021;518:59\u201371.","journal-title":"Cancer Lett"},{"key":"3960_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2308097","author":"GS Santiago-S\u00e1nchez","year":"2024","unstructured":"Santiago-S\u00e1nchez GS, Fabian KP, Hodge JW. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biol Ther. 2024. https:\/\/doi.org\/10.1080\/15384047.2024.2308097.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3960_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058935","volume":"8","author":"M El-Zaatari","year":"2013","unstructured":"El-Zaatari M, Kao JY, Tessier A, Bai L, Hayes MM, Fontaine C, et al. Gli1 deletion prevents Helicobacter-induced gastric metaplasia and expansion of myeloid cell subsets. PLoS ONE. 2013;8(3): e58935.","journal-title":"PLoS ONE"},{"issue":"11","key":"3960_CR86","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00407-21","volume":"89","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wu Y, Li H, Li C, Yan L, Li Q. Plasmacytoid dendritic cell-derived type i interferon is involved in helicobacter pylori infection-induced differentiation of schlafen 4-expressing myeloid-derived suppressor cells. Infect Immun. 2021;89(11): e0040721.","journal-title":"Infect Immun"},{"issue":"8","key":"3960_CR87","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1172\/JCI82529","volume":"126","author":"L Ding","year":"2016","unstructured":"Ding L, Hayes MM, Photenhauer A, Eaton KA, Li Q, Ocadiz-Ruiz R, et al. Schlafen 4-expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia. J Clin Invest. 2016;126(8):2867\u201380.","journal-title":"J Clin Invest"},{"issue":"2","key":"3960_CR88","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2022.04.031","volume":"163","author":"L Ding","year":"2022","unstructured":"Ding L, Chakrabarti J, Sheriff S, Li Q, Thi Hong HN, Sontz RA, et al. Toll-like receptor 9 pathway mediates schlafen+-MDSC polarization during helicobacter-induced gastric metaplasias. Gastroenterology. 2022;163(2):411-425.e4.","journal-title":"Gastroenterology"},{"key":"3960_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0803-7","author":"FY Mao","year":"2018","unstructured":"Mao FY, Zhao YL, Lv YP, Teng YS, Kong H, Liu YG, et al. CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6\/IL-8-arginase I axis in human gastric cancer. Cell Death Dis. 2018. https:\/\/doi.org\/10.1038\/s41419-018-0803-7.","journal-title":"Cell Death Dis"},{"issue":"10","key":"3960_CR90","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/gutjnl-2019-318817","volume":"69","author":"L Ding","year":"2020","unstructured":"Ding L, Li Q, Chakrabarti J, Munoz A, Faure-Kumar E, Ocadiz-Ruiz R, et al. MiR130b from Schlafen4+ MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer. Gut. 2020;69(10):1750\u201361.","journal-title":"Gut"},{"key":"3960_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8121995","author":"Y Hayakawa","year":"2020","unstructured":"Hayakawa Y, Hirata Y, Hata M, Tsuboi M, Oya Y, Kurokawa K, et al. Dysregulated immune responses by ASK1 deficiency alter epithelial progenitor cell fate and accelerate metaplasia development during H. pylori Infection. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8121995.","journal-title":"Microorganisms"},{"issue":"9","key":"3960_CR92","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/gutjnl-2014-307020","volume":"64","author":"Y Zhuang","year":"2015","unstructured":"Zhuang Y, Cheng P, Fei LX, Sheng PL, Sheng LB, Ting WT, et al. A proinflammatory role for Th22 cells in Helicobacter pylori-associated gastritis. Gut. 2015;64(9):1368\u201378.","journal-title":"Gut"},{"key":"3960_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007468","author":"L Holokai","year":"2019","unstructured":"Holokai L, Chakrabarti J, Broda T, Chang J, Hawkins JA, Sundaram N, et al. Increased programmed death-ligand 1 is an early epithelial cell response to helicobacter pylori infection. PLoS Pathog. 2019. https:\/\/doi.org\/10.1371\/journal.ppat.1007468.","journal-title":"PLoS Pathog"},{"issue":"9","key":"3960_CR94","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1128\/IAI.00553-07","volume":"75","author":"EJ Beswick","year":"2007","unstructured":"Beswick EJ, Pinchuk IV, Das S, Powell DW, Reyes VE. Expression of the programmed death ligand 1, B7\u2013H1, on gastric epithelial cells after helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells. Infect Immun. 2007;75(9):4334\u201341. https:\/\/doi.org\/10.1128\/IAI.00553-07.","journal-title":"Infect Immun"},{"key":"3960_CR95","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gene.2017.02.025","volume":"611","author":"AM Ghaleb","year":"2017","unstructured":"Ghaleb AM, Yang VW. Kr\u00fcppel-like factor 4 (KLF4): what we currently know. Gene. 2017;611:27\u201337.","journal-title":"Gene"},{"issue":"1","key":"3960_CR96","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10120-018-0833-y","volume":"22","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhu Z, Wu H, Yu Z, Rong Z, Luo Z, et al. PODXL, negatively regulated by KLF4, promotes the EMT and metastasis and serves as a novel prognostic indicator of gastric cancer. Gastric Cancer. 2019;22(1):48\u201359.","journal-title":"Gastric Cancer"},{"issue":"9","key":"3960_CR97","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2174\/15680096113136660104","volume":"13","author":"J Cui","year":"2013","unstructured":"Cui J, Shi M, Quan M, Xie K. Regulation of EMT by KLF4 in gastrointestinal cancer. Curr Cancer Drug Targets. 2013;13(9):986\u201395.","journal-title":"Curr Cancer Drug Targets"},{"key":"3960_CR98","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.molimm.2019.11.014","volume":"117","author":"BH Li","year":"2020","unstructured":"Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol Immunol. 2020;117:201\u201315.","journal-title":"Mol Immunol"},{"key":"3960_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2021.06.009","author":"EM Ayd\u0131n","year":"2021","unstructured":"Ayd\u0131n EM, Demir TD, Seymen N, Said SS, Oktem-Okullu S, Tiftikci A, et al. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer. Immunol Lett. 2021. https:\/\/doi.org\/10.1016\/j.imlet.2021.06.009.","journal-title":"Immunol Lett"},{"key":"3960_CR100","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.2147\/CMAR.S203035","volume":"11","author":"B Shen","year":"2019","unstructured":"Shen B, Qian A, Lao W, Li W, Chen X, Zhang B, et al. Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer. Cancer Manag Res. 2019;11:3909\u201319.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"3960_CR101","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jcmgh.2021.04.007","volume":"12","author":"DM Go","year":"2021","unstructured":"Go DM, Lee SH, Lee SH, Woo SH, Kim K, Kim K, et al. Programmed death ligand 1-expressing classical dendritic cells mitigate helicobacter-induced gastritis. Cell Mol Gastroenterol Hepatol. 2021;12(2):715\u201339.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3960_CR102","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26473","author":"J Chakrabarti","year":"2018","unstructured":"Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J, et al. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget. 2018. https:\/\/doi.org\/10.18632\/oncotarget.26473.","journal-title":"Oncotarget"},{"issue":"3","key":"3960_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121841","volume":"10","author":"TT Lina","year":"2015","unstructured":"Lina TT, Alzahrani S, House J, Yamaoka Y, Sharpe AH, Rampy BA, et al. Helicobacter pylori cag pathogenicity island\u2019s role in B7\u2013H1 induction and immune evasion. PLoS ONE. 2015;10(3): e0121841.","journal-title":"PLoS ONE"},{"issue":"9","key":"3960_CR104","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxab044","volume":"33","author":"J Wu","year":"2021","unstructured":"Wu J, Zhu X, Guo X, Yang Z, Cai Q, Gu D, et al. Helicobacter urease suppresses cytotoxic CD8+ T-cell responses through activating Myh9-dependent induction of PD-L1. Int Immunol. 2021;33(9):491\u2013504. https:\/\/doi.org\/10.1093\/intimm\/dxab044.","journal-title":"Int Immunol"},{"issue":"12","key":"3960_CR105","doi-asserted-by":"publisher","first-page":"9997","DOI":"10.1002\/jcb.27329","volume":"119","author":"H Li","year":"2018","unstructured":"Li H, Xia JQ, Zhu FS, Xi ZH, Pan CY, Gu LM, et al. LPS promotes the expression of PD-L1 in gastric cancer cells through NF-kappaB activation. J Cell Biochem [Internet]. 2018;119(12):9997\u201310004. https:\/\/doi.org\/10.1002\/jcb.27329.","journal-title":"J Cell Biochem [Internet]."},{"key":"3960_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215598","volume":"532","author":"X Zhou","year":"2022","unstructured":"Zhou X, Fang D, Liu H, Ou X, Zhang C, Zhao Z, et al. PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer. Cancer Lett. 2022;532: 215598.","journal-title":"Cancer Lett"},{"key":"3960_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.334","author":"X Yuan","year":"2013","unstructured":"Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis. 2013. https:\/\/doi.org\/10.1038\/cddis.2013.334.","journal-title":"Cell Death Dis"},{"key":"3960_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979116","author":"L Fang","year":"2022","unstructured":"Fang L, Liu K, Liu C, Wang X, Ma W, Xu W, et al. Tumor accomplice: T cell exhaustion induced by chronic inflammation. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.979116.","journal-title":"Front Immunol"},{"issue":"10","key":"3960_CR109","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neo.2014.08.013","volume":"16","author":"EI Deryugina","year":"2014","unstructured":"Deryugina EI, Zajac E, Juncker-Jensen A, Kupriyanova TA, Welter L, Quigley JP. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia octubre de. 2014;16(10):771\u201388.","journal-title":"Neoplasia octubre de"},{"key":"3960_CR110","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1004983","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Wu T, Shao S, Shi B, Zhao Y. Phenotype, development, and biological function of myeloid-derived suppressor cells. Oncoimmunology. 2015. https:\/\/doi.org\/10.1080\/2162402X.2015.1004983.","journal-title":"Oncoimmunology."},{"issue":"7","key":"3960_CR111","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.20050715","volume":"202","author":"PC Rodriguez","year":"2005","unstructured":"Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931\u20139.","journal-title":"J Exp Med"},{"issue":"7","key":"3960_CR112","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1172\/JCI131859","volume":"130","author":"MH Oh","year":"2020","unstructured":"Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest. 2020;130(7):3865\u201384.","journal-title":"J Clin Invest"},{"key":"3960_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","volume":"235","author":"S Joshi","year":"2022","unstructured":"Joshi S, Sharabi A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol Ther julio de. 2022;235: 108114.","journal-title":"Pharmacol Ther julio de"},{"key":"3960_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.192","author":"SL Jian","year":"2017","unstructured":"Jian SL, Chen WW, Su YC, Su YW, Chuang TH, Hsu SC, et al. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis. 2017. https:\/\/doi.org\/10.1038\/cddis.2017.192.","journal-title":"Cell Death Dis"},{"key":"3960_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-13-18","author":"I Hammami","year":"2012","unstructured":"Hammami I, Chen J, Murschel F, Bronte V, De Crescenzo G, Jolicoeur M. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol. 2012. https:\/\/doi.org\/10.1186\/1471-2121-13-18.","journal-title":"BMC Cell Biol"},{"key":"3960_CR116","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41419-020-03175-5","volume":"11","author":"M Cerezo","year":"2020","unstructured":"Cerezo M, Rocchi S. Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. Cell Death Dis [Internet]. 2020;11:964. https:\/\/doi.org\/10.1038\/s41419-020-03175-5.","journal-title":"Cell Death Dis [Internet]."},{"key":"3960_CR117","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fimmu.2019.01399","volume":"10","author":"D Yan","year":"2019","unstructured":"Yan D, Adeshakin AO, Xu M, Afolabi LO, Zhang G, Chen YH, et al. Lipid Metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in tumor. Front Immunol. 2019;10:1399.","journal-title":"Front Immunol"},{"issue":"5","key":"3960_CR118","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.it.2018.01.012","volume":"39","author":"MH den Brok","year":"2018","unstructured":"den Brok MH, Raaijmakers TK, Collado-Camps E, Adema GJ. Lipid droplets as immune modulators in myeloid cells. Trends Immunol mayo de. 2018;39(5):380\u201392.","journal-title":"Trends Immunol mayo de"},{"issue":"11","key":"3960_CR119","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res noviembre de. 2015;3(11):1236\u201347.","journal-title":"Cancer Immunol Res noviembre de"},{"key":"3960_CR120","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.03.001","volume":"151","author":"NA Warfel","year":"2015","unstructured":"Warfel NA, Kraft AS. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther julio de. 2015;151:41\u20139.","journal-title":"Pharmacol Ther julio de"},{"issue":"4","key":"3960_CR121","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1158\/2326-6066.CIR-20-0433","volume":"9","author":"G Xin","year":"2021","unstructured":"Xin G, Chen Y, Topchyan P, Kasmani MY, Burns R, Volberding PJ, et al. Targeting Pim1-mediated metabolism in myeloid suppressor cells to treat cancer. Cancer Immunol Res. 2021;9(4):454\u201369. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0433.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"3960_CR122","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y, et al. Lactate-Modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res noviembre de. 2020;8(11):1440\u201351.","journal-title":"Cancer Immunol Res noviembre de"},{"key":"3960_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.901495","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhai Z, Duan J, Wang X, Zhong J, Wu L, et al. Lactate: the mediator of metabolism and immunosuppression. Front Endocrinol (Lausanne). 2022;13: 901495.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3960_CR124","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/icb.2013.29","volume":"91","author":"YS Khaled","year":"2013","unstructured":"Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol [Internet]. 2013;91:493\u2013502. https:\/\/doi.org\/10.1038\/icb.2013.29.","journal-title":"Immunol Cell Biol [Internet]."},{"issue":"6","key":"3960_CR125","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1320011","volume":"6","author":"J Li","year":"2017","unstructured":"Li J, Wang L, Chen X, Li L, Li Y, Ping Y, et al. CD39\/CD73 upregulation on myeloid-derived suppressor cells via TGF-\u03b2-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology. 2017;6(6): e1320011.","journal-title":"Oncoimmunology"},{"issue":"10","key":"3960_CR126","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2326-6066.CIR-19-0008","volume":"7","author":"A Holtzhausen","year":"2019","unstructured":"Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y, et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments Anti-PD-1 therapy in melanoma. Cancer Immunol Res octubre de. 2019;7(10):1672\u201386.","journal-title":"Cancer Immunol Res octubre de"},{"issue":"5","key":"3960_CR127","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nri2303","volume":"8","author":"G Lemke","year":"2008","unstructured":"Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol mayo de. 2008;8(5):327\u201336.","journal-title":"Nat Rev Immunol mayo de"},{"issue":"3","key":"3960_CR128","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the Pd1 inhibitory pathway. Nat Rev Immunol [Internet]. 2018;18(3):153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol [Internet]."},{"issue":"3","key":"3960_CR129","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.gastro.2020.10.036","volume":"160","author":"W Kim","year":"2021","unstructured":"Kim W, Chu TH, Nienh\u00fcser H, Jiang Z, Del Portillo A, Remotti HE, et al. PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. Gastroenterology febrero de. 2021;160(3):781\u201396.","journal-title":"Gastroenterology febrero de"},{"issue":"6","key":"3960_CR130","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med junio de. 2020;26(6):878\u201385.","journal-title":"Nat Med junio de"},{"issue":"137","key":"3960_CR131","first-page":"99","volume":"25","author":"N Li","year":"2018","unstructured":"Li N, Han D, Sun J, Li Y, Zhang J, Zhang Y, et al. Subtypes of MDSCs in mechanisms and prognosis of gastric cancer and are inhibited by epirubicin and paclitaxel. Discov Med. 2018;25(137):99\u2013112.","journal-title":"Discov Med"},{"issue":"8","key":"3960_CR132","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361.","journal-title":"Cancer Res"},{"issue":"31","key":"3960_CR133","doi-asserted-by":"publisher","first-page":"32228","DOI":"10.18632\/oncotarget.4772","volume":"6","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf EM, Santegoets SJAM, Reyners AKL, Goedemans R, Nijman HW, van Poelgeest MIE, et al. A phase 1\/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 2015;6(31):32228\u201343.","journal-title":"Oncotarget"},{"key":"3960_CR134","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8307","author":"MJ Welters","year":"2016","unstructured":"Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/scitranslmed.aad8307.","journal-title":"Sci Transl Med"},{"issue":"22","key":"3960_CR135","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","volume":"130","author":"FR Appelbaum","year":"2017","unstructured":"Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130(22):2373\u20136.","journal-title":"Blood"},{"issue":"8","key":"3960_CR136","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood.2019003471","volume":"135","author":"E Fournier","year":"2020","unstructured":"Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020;135(8):542\u20136.","journal-title":"Blood"},{"key":"3960_CR137","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ebiom.2019.08.025","volume":"47","author":"L Fultang","year":"2019","unstructured":"Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N, et al. MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine septiembre de. 2019;47:235\u201346.","journal-title":"EBioMedicine septiembre de"},{"issue":"9","key":"3960_CR138","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","volume":"73","author":"J Xu","year":"2013","unstructured":"Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Re. 2013;73(9):2782\u201394.","journal-title":"Cancer Re"},{"issue":"7","key":"3960_CR139","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2009-08-237412","volume":"115","author":"SJ Priceman","year":"2010","unstructured":"Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115(7):1461\u201371.","journal-title":"Blood"},{"key":"3960_CR140","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol octubre de. 2018;63:282\u201391.","journal-title":"Int Immunopharmacol octubre de"},{"issue":"22","key":"3960_CR141","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67(22):11021\u20138.","journal-title":"Cancer Res"},{"issue":"12","key":"3960_CR142","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/0008-5472.CAN-17-3415","volume":"78","author":"R Bauer","year":"2018","unstructured":"Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 2018;78(12):3220\u201332.","journal-title":"Cancer Res"},{"issue":"24","key":"3960_CR143","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.3390\/cancers13246293","volume":"13","author":"K Bullock","year":"2021","unstructured":"Bullock K, Richmond A. Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. Cancers (Basel). 2021;13(24):6293.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3960_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007699","volume":"11","author":"PT Magahis","year":"2023","unstructured":"Magahis PT, Maron SB, Cowzer D, King S, Schattner M, Janjigian Y, et al. Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer octubre de. 2023;11(10): e007699.","journal-title":"J Immunother Cancer octubre de"},{"issue":"2","key":"3960_CR145","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.mehy.2007.05.045","volume":"70","author":"LJ Xue","year":"2008","unstructured":"Xue LJ, Su QS, Yang JH, Lin Y. Autoimmune responses induced by helicobacter pylori improve the prognosis of gastric carcinoma. Med Hypotheses [Internet]. 2008;70(2):273\u20136. https:\/\/doi.org\/10.1016\/j.mehy.2007.05.045.","journal-title":"Med Hypotheses [Internet]."},{"key":"3960_CR146","doi-asserted-by":"publisher","DOI":"10.4172\/1948-5956.1000198","author":"J Periasamy","year":"2013","unstructured":"Periasamy J, Muthuswami M, Ramesh V, Muthusamy T, Jain A, et al. Nimesulide and celecoxib inhibits multiple oncogenic pathways in gastric cancer cells. J Cancer Sci Ther. 2013. https:\/\/doi.org\/10.4172\/1948-5956.1000198.","journal-title":"J Cancer Sci Ther"},{"issue":"4","key":"3960_CR147","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41588-023-01333-x","volume":"55","author":"Y Totoki","year":"2023","unstructured":"Totoki Y, Saito-Adachi M, Shiraishi Y, Komura D, Nakamura H, Suzuki A, et al. Multiancestry genomic and transcriptomic analysis of gastric cancer. Nat Genet abril de. 2023;55(4):581\u201394.","journal-title":"Nat Genet abril de"},{"key":"3960_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/srep13750","author":"J Zhang","year":"2015","unstructured":"Zhang J, Huang JY, Chen YN, Yuan F, Zhang H, Yan FH, et al. Whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma. Sci Rep. 2015. https:\/\/doi.org\/10.1038\/srep13750.","journal-title":"Sci Rep"},{"issue":"12","key":"3960_CR149","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691\u2013702.","journal-title":"J Exp Med"},{"issue":"1","key":"3960_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4251\/wjgo.v13.i1.1","volume":"13","author":"M Farshidpour","year":"2021","unstructured":"Farshidpour M, Ahmed M, Junna S, Merchant JL. Myeloid-derived suppressor cells in gastrointestinal cancers: a systemic review. World J Gastrointest Oncol. 2021;13(1):1\u201311.","journal-title":"World J Gastrointest Oncol"},{"key":"3960_CR151","doi-asserted-by":"publisher","first-page":"10","DOI":"10.17352\/2455-8591.000022","volume":"6","author":"D Rawat","year":"2020","unstructured":"Rawat D, Koiri RK. Tadalafil inhibits elevated glutamic oxaloacetic transaminase during alcohol aflatoxin induced hepatocellular carcinoma in rats. Int J Immunother Cancer Res. 2020;6:10\u20133.","journal-title":"Int J Immunother Cancer Res"},{"issue":"6","key":"3960_CR152","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","volume":"69","author":"J Ozao-Choy","year":"2009","unstructured":"Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69(6):2514\u201322.","journal-title":"Cancer Res"},{"issue":"3","key":"3960_CR153","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","volume":"39","author":"JE Cheong","year":"2018","unstructured":"Cheong JE, Sun L. Targeting the IDO1\/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities. Trends Pharmacol Sci marzo de. 2018;39(3):307\u201325.","journal-title":"Trends Pharmacol Sci marzo de"},{"key":"3960_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807271","volume":"13","author":"F Peyraud","year":"2022","unstructured":"Peyraud F, Guegan JP, Bodet D, Cousin S, Bessede A, Italiano A. Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives. Front Immunol. 2022;13: 807271.","journal-title":"Front Immunol"},{"issue":"4","key":"3960_CR155","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.immuni.2020.03.004","volume":"52","author":"E Mohamed","year":"2024","unstructured":"Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity. 2024;52(4):668\u201382.","journal-title":"Immunity"},{"key":"3960_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00356","author":"P Lasso","year":"2018","unstructured":"Lasso P, Gomez-Cadena A, Uruena C, et al. Prophylactic vs. therapeutic treatment with P2Et polyphenol-rich extract has opposite efects on tumor growth. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00356.","journal-title":"Front Oncol"},{"key":"3960_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fmmu.2020.584959","author":"P Lasso","year":"2020","unstructured":"Lasso P, Gomez-Cadena A, Uruena C, et al. An immunomodulatory gallotanin-rich fraction from caesalpinia spinosa enhances the therapeutic efect of anti-PD-L1 in melanoma. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fmmu.2020.584959.","journal-title":"Front Immunol"},{"key":"3960_CR158","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20201170","author":"Y Wang","year":"2020","unstructured":"Wang Y, Fan X, Wu X. Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-\u03baB-IDO pathway. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20201170."},{"key":"3960_CR159","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.intimp.2016.07.035","volume":"39","author":"D Liu","year":"2016","unstructured":"Liu D, You M, Xu Y, Li F, Zhang D, Li X, et al. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Int Immunopharmacol octubre de. 2016;39:265\u201372.","journal-title":"Int Immunopharmacol octubre de"},{"issue":"2","key":"3960_CR160","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/mt.2015.165","volume":"24","author":"Y Lu","year":"2016","unstructured":"Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, et al. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther febrero de. 2016;24(2):364\u201374.","journal-title":"Mol Ther febrero de"},{"issue":"2","key":"3960_CR161","first-page":"645","volume":"35","author":"NG Vallianou","year":"2015","unstructured":"Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res febrero de. 2015;35(2):645\u201351.","journal-title":"Anticancer Res febrero de"},{"issue":"7","key":"3960_CR162","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","volume":"29","author":"RP Tobin","year":"2023","unstructured":"Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, et al. Targeting MDSC differentiation using ATRA: A Phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. Clin Cancer Res. 2023;29(7):1209\u201319.","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl 11","key":"3960_CR163","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol agosto de. 1995;22(4 Suppl 11):3\u201310.","journal-title":"Semin Oncol agosto de"},{"key":"3960_CR164","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2051-1426-1-10","volume":"1","author":"R Wesolowski","year":"2013","unstructured":"Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1:10.","journal-title":"J Immunother Cancer"},{"key":"3960_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030561","author":"AMK Law","year":"2020","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9030561.","journal-title":"Cells"},{"issue":"6","key":"3960_CR166","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148\u201357.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3960_CR167","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","volume":"70","author":"JS Ko","year":"2010","unstructured":"Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70(9):3526\u201336.","journal-title":"Cancer Res"},{"key":"3960_CR168","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007974","author":"SL Highfill","year":"2014","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/scitranslmed.3007974.","journal-title":"Sci Transl Med"},{"issue":"8","key":"3960_CR169","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","volume":"4","author":"JE Lancet","year":"2020","unstructured":"Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, et al. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020;4(8):1683\u20139.","journal-title":"Blood Adv"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03960-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03960-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03960-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:03:12Z","timestamp":1763568192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03960-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":169,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3960"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03960-8","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20201170","asserted-by":"subject"}]},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies directly involving human participants, as it is a review of data already collected in a database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent for this type of study is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}